Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), …
September 2024 FDA Roundup: Key Decisions Drive Oncology …
Oct 2, 2024 · FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML. ICT01, a humanized anti-BTN3A monoclonal antibody, plus azacitidine and venetoclax …
FDA Grants Priority Review to Durvalumab in MIBC
Dec 6, 2024 · Behind the Phase 3 NIAGARA Trial. NIAGARA is a randomized, open-label, multicenter, global trial which enrolled adult patients with cisplatin-eligible MIBC with a clinical …
Advances in Targeted Therapies for SCLC Care
Oct 30, 2024 · Ariel Lopez-Chavez, MD, medical oncologist, director of precision medicine and developmental therapeutics at Allegheny Health Network Cancer Institute, provides an …
Does Odronextamab Show Hope in FL and DLBCL Despite …
Nov 5, 2024 · “This study yielded some very good overall response rates of 80%, and mostly complete response rates. Those responses were durable, with a median duration of response …
Tremelimumab Plus Durvalumab Turns Heads With Updated Five …
Sep 16, 2024 · Updated 5-year data from the phase 3 HIMALAYA study (NCT03298451) showed that the combination of single tremelimumab (Imjudo) with a regular interval of durvalumab …
FDA Approves Frontline Pembrolizumab/Chemotherapy in …
Sep 18, 2024 · During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients …
Revumenib for NPM1-Mutant AML Succeeds in Pivotal Trial
Nov 12, 2024 · In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in …
Cilta-Cel Improves Overall Survival in Multiple Myeloma
Sep 30, 2024 · Treatment with the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) reduced the risk of death by 45% vs standard of care (SOC) in patients with …
Discussion of Real-World Myeloma Care Emphasizes Value of …
Dec 6, 2024 · Samer A. Al’Hadidi, MD, assistant professor in the Department of Internal Medicine — Division of Hematology and Oncology at UAMS Winthrop P. Rockefeller Cancer Institute in …